Scholarlink

Introduction <p>Tecovirimat (TPOXX) is an effective antiviral medication recommended for treating smallpox and other <i>Orthopoxvirus</i> infections. With the rise in monkeypox (mpox) cases globally, there is an urgent need to explore therapeutic options to manage potential outbreaks.</p> Methodology <p>A literature search was conducted using keywords from Scopus and ClinicalTrials.gov. English studies from 2018 to 2024 were included.</p> Results <p>Ten studies assessing the effectiveness and safety of tecovirimat for poxvirus infections were evaluated, reporting diverse findings across different patient populations and study designs. Clinical trials have shown significant therapeutic potential. Various doses of tecovirimat were used in rabbit and mpox models. Early intervention slowed disease progression in vulnerable populations, such as people living with HIV (PLWHIV). Recovery times, virus eradication, and symptom relief varied among studies, but wider access and usage showed better clinical symptoms and tolerable side effects. Tecovirimat’s efficacy against circulating strains has been experimentally demonstrated.</p> Conclusion <p>Tecovirimat shows promise for treating poxvirus infections. Clinical trials are expected to provide more evidence-based findings to inform future therapeutic approaches and public health campaigns. Future research should explore tecovirimat’s potential in managing emerging poxvirus outbreaks, such as borealpox and mpox, to strengthen and promote public health.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tecovirimat in the management of poxviruses: a narrative review of available evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月6日

查看全文
  • Olalekan John Okesanya,
  • Jerico Bautista Ogaya,
  • Ikponmwosa Jude Ogieuhi,
  • Mohamed Mustaf Ahmed,
  • Bonaventure Michael Ukoaka,
  • Ojoisimi Franca Jamgbadi,
  • Deborah Oluwaseun Shomuyiwa,
  • Don Lucero-Prisno Eliseo III,
  • Blessing Olawunmi Amisu,
  • Olakulehin Adebusuyi,
  • William K. Chung,
  • Emery Manirambona,
  • Nimat Bola Idris,
  • Janet Alexis A. De los Santos

摘要

Introduction

Tecovirimat (TPOXX) is an effective antiviral medication recommended for treating smallpox and other Orthopoxvirus infections. With the rise in monkeypox (mpox) cases globally, there is an urgent need to explore therapeutic options to manage potential outbreaks.

Methodology

A literature search was conducted using keywords from Scopus and ClinicalTrials.gov. English studies from 2018 to 2024 were included.

Results

Ten studies assessing the effectiveness and safety of tecovirimat for poxvirus infections were evaluated, reporting diverse findings across different patient populations and study designs. Clinical trials have shown significant therapeutic potential. Various doses of tecovirimat were used in rabbit and mpox models. Early intervention slowed disease progression in vulnerable populations, such as people living with HIV (PLWHIV). Recovery times, virus eradication, and symptom relief varied among studies, but wider access and usage showed better clinical symptoms and tolerable side effects. Tecovirimat’s efficacy against circulating strains has been experimentally demonstrated.

Conclusion

Tecovirimat shows promise for treating poxvirus infections. Clinical trials are expected to provide more evidence-based findings to inform future therapeutic approaches and public health campaigns. Future research should explore tecovirimat’s potential in managing emerging poxvirus outbreaks, such as borealpox and mpox, to strengthen and promote public health.